Can-Fite BioPharma
CANF • XASE
Can-Fite BioPharma is a publicly traded company trading on XASE, led by CEO Motti Farbstein.
CEOMotti Farbstein
Next Earnings
No upcoming earnings scheduled for Can-Fite BioPharma
No earnings announcement scheduled
Earnings History
Past 12 earnings reports for Can-Fite BioPharma
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 26, 2026 | FY 2025 | -$5.97Est: -$10.40 | +42.6% | $405.0KEst: $202.0K | +100.5% | — |
| Aug 29, 2024 | H1 2024 | $0.00Est: -$0.40 | +100.0% | $316.0KEst: $150.0K | +110.7% | — |
| Mar 28, 2024 | Q4 2023 | -$0.01Est: -$0.26 | +96.2% | $155.0KEst: $100.0K | +55.0% | — |
| Nov 30, 2023 | Q3 2023 | -$0.43Est: -$0.44 | +2.3% | $196.0KEst: $100.0K | +96.0% | — |
| Aug 31, 2023 | Q2 2023 | -$0.40Est: -$0.42 | +4.8% | $196.0KEst: $100.0K | +96.0% | — |
| Jun 1, 2023 | Q1 2023 | -$0.65Est: -$1.52 | +57.2% | $196.0K | — | — |
| Mar 30, 2023 | Q4 2022 | -$1.11Est: -$0.98 | -13.3% | $197.0KEst: $330.0K | -40.3% | — |
| Nov 25, 2022 | Q3 2022 | -$0.10Est: -$1.10 | +90.9% | $204.0KEst: $200.0K | +2.0% | — |
| Aug 25, 2022 | Q2 2022 | -$0.80Est: -$1.00 | +20.0% | $204.0K | — | — |
| May 26, 2022 | Q1 2022 | $0.00Est: -$1.40 | +100.0% | $205.0KEst: $200.0K | +2.5% | — |
| Mar 24, 2022 | Q4 2021 | -$0.10Est: -$1.80 | +94.4% | $204.0KEst: $250.0K | -18.4% | — |
| Nov 26, 2021 | Q3 2021 | -$0.20Est: -$0.90 | +77.8% | $251.0KEst: $150.0K | +67.3% | — |